Shivalik Rasayan Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SHIVALIK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shivalik Rasayan Limited announced its unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone net sales grew strongly by about 47% year-on-year to Rs. 4,626.45 lakhs (from Rs. 3,158.11 lakhs), while consolidated revenue rose to Rs. 8,930.93 lakhs (up about 20% YoY). However, standalone net profit fell sharply by about 60% to Rs. 122.08 lakhs (from Rs. 306.92 lakhs), and consolidated net profit declined about 27% to Rs. 282.13 lakhs, indicating clear margin compression even as top-line grew. The API segment continues to post losses of about Rs. 296 lakhs. The Board also approved incorporating a wholly owned subsidiary for pesticide formulations (forward integration), re-designated an executive director to non-executive role, and proposed a final dividend of Rs. 0.50 per share subject to AGM approval on September 27, 2025.
Mixed for shareholders: strong revenue growth driven by the agrochemical and pharma formulation segments is a positive, but sharply falling profits and continued losses in the API segment may pressure the stock in the short term. The proposed new subsidiary for pesticide formulations and the final dividend are mild positives for long-term and income investors.